An explanation of the variable clinical response to interleukin 2 and LAK cells

This publication has 28 references indexed in Scilit:

• Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia.
  The Journal of Experimental Medicine, 1989
• Immunotherapy of cancer using interleukin 2: current status and future prospects
  Immunology Today, 1988
• Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma
  New England Journal of Medicine, 1988
• Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
  The Journal of Experimental Medicine, 1988
• Human Cytotoxic T Cells Specific for Autologous Melanoma Cells: Successful Generation From Lymph Node Cells in Seven Consecutive Cases
  JNCI Journal of the National Cancer Institute, 1988
• In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2
  International Journal of Cancer, 1988
• Increased Vascular Permeability in Organs Mediated by the Systemic Administration of Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 in Mice
  JNCI Journal of the National Cancer Institute, 1988
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
  New England Journal of Medicine, 1987
• Clonal analysis of cytotoxic T cell response against human melanoma.
  The Journal of Experimental Medicine, 1983